Heron's Ground­hog Day; Vi­for forms JV with Fre­se­nius Kabi in Chi­na

→ An­oth­er de­lay has blight­ed Heron Ther­a­peu­tics‘ quest to get its long-act­ing non-opi­oid painkiller for post-sur­gi­cal anal­ge­sia on to the US mar­ket. The com­pa­ny, whose prod­uct is meant to ri­val Paci­ra’s J&J-part­nered, long-act­ing post-op painkiller Ex­par­el, was hand­ed an un­ex­pect­ed CRL last year af­ter the FDA asked for more da­ta re­lat­ing to chem­istry, man­u­fac­tur­ing, and con­trols as well as non-clin­i­cal in­for­ma­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER